Ownership Vs. Contract: How Vertical Integration Affects Investment Decisions in Pharmaceutical R&D
56 Pages Posted: 7 Mar 2005 Last revised: 8 Feb 2014
There are 2 versions of this paper
Ownership Vs. Contract: How Vertical Integration Affects Investment Decisions in Pharmaceutical R&D
Ownership vs. Contract: How Vertical Integration Affects Investment Decisions in Pharmaceutical R&D
Date Written: October 1, 2005
Abstract
This paper explores the effect of vertical integration on investment behavior in the pharmaceutical industry. I study a detailed, project-level sample of 4057 drug candidates that were sponsored by 40 large pharmaceutical firms during the period 1984-2001. Of these projects, 447 were conducted through a contractual alliance with another, smaller company that had discovered the drug candidate. The existence of these two types of governance structures allows me to compare integrated and non-integrated projects within the same firm. Controlling for project and firm characteristics, I document that pharmaceutical firms are more selective in continuing their integrated projects than in continuing projects governed by contract. I hypothesize that this difference is caused by the rigidity of the contract that governs non-integrated projects, making them less flexible in adapting to changes in the firm's situation. In line with this hypothesis, I document that although more frequently continued, non-integrated projects have a lower probability of success. Moreover, investment in non-integrated projects is less sensitive to the firm's cash flow and to the existence of other projects in the firm.
Keywords: Vertical Integration, Investment Decisions, Internal Capital Markets, Pharmaceutical Industry
JEL Classification: G32, L22, L65
Suggested Citation: Suggested Citation
Do you have negative results from your research you’d like to share?
Recommended Papers
-
Do Equity Financing Cycles Matter?: Evidence from Biotechnology Alliances
By Alexander Tsai and Josh Lerner
-
Do Equity Financing Cycles Matter? Evidence from Biotechnology Alliances
By Alexander Tsai and Josh Lerner
-
By Ilan Guedj and David S. Scharfstein
-
By Ilan Guedj and David S. Scharfstein
-
Biotech-Pharmaceutical Alliances as a Signal of Asset and Firm Quality
By Sean Nicholson, Patricia M. Danzon, ...
-
Financial Contracting in Biotech Strategic Alliances
By David T. Robinson and Toby Stuart
-
Contractibility and the Design of Research Agreements
By Ulrike Malmendier and Josh Lerner
-
Contractibility and the Design of Research Agreements
By Ulrike Malmendier and Josh Lerner
-
Productivity in Pharmaceutical Biotechnology R&D: The Role of Experience and Alliances
By Patricia M. Danzon, Sean Nicholson, ...